法国ASSIST-ICD登记:左心室辅助装置治疗现状
基于法国20家植入中心的671例左心室辅助装置(LVAD)受体,ASSIST-ICD多中心登记回顾性分析了2007至2016年的临床数据。1、2、3、5年生存或移植的主要终点分别为65.2%、59.7%、55.9%和47.7%,5年累计移植发生率为29.2%。尽管患者平均年龄更大且更多被选为终点治疗,生存率较既往国家登记改善。
要点
- 法国LVAD真实世界1年生存或移植率为65.2%,5年为47.7%。
- 主要并发症包括驱动线感染26.1%、泵袋/套管感染12.6%、LVAD血栓12.2%。
- 植入时53%患者处于心源性休克,21.5%使用体外生命支持。
核心结论
- ASSIST-ICD登记显示法国LVAD患者病情更重,但生存率较既往国家登记改善。
- 建议更早转诊LVAD,并讨论桥接患者移植的最佳时机。
研究设计与样本
- 多中心回顾性登记研究,纳入法国24家LVAD植入中心中20家的671例受体。
- 收集136个变量,平均随访1.2年(标准差1.4),总随访807.5患者年。
主要发现
- 1、2、3、5年生存或移植的主要终点分别为65.2%、59.7%、55.9%和47.7%。
- 5年累计移植发生率为29.2%。
- 主要并发症:驱动线感染26.1%、泵袋或套管感染12.6%、LVAD血栓12.2%、缺血性卒中12.8%、出血性卒中5.4%、所有卒中18.2%、非脑出血9.1%、LVAD更换5.2%。
- 植入时53%患者处于心源性休克,21.5%使用体外生命支持。
临床怎么用
- 应更早转诊适合LVAD的患者,避免过晚植入。
- 桥接移植患者需讨论最佳移植时机,因支持第二年后的结果可能更差。
局限性
- 平均随访时间较短(1.2年),可能影响长期结局评估。
- 仅纳入法国20家中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our goal was to provide a picture of left ventricular assist device (LVAD) activity in France between 2007 and 2016 based on the multicentric ASSIST-ICD registry. METHODS: We retrospectively collected 136 variables including in-hospital data, follow-up survival rates and adverse events from 671 LVAD recipients at 20 out of 24 LVAD implant centres in France. The average follow-up time was 1.2 years (standard deviation: 1.4); the total follow-up time was 807.5 patient-years. RESULTS: The included devices were the HeartMate II®, HeartWare LVAS® or Jarvik 2000®. The overall likelihood of being alive while on LVAD support or having a transplant (primary end point) at 1, 2, 3 and 5 years postimplantation was 65.2%, 59.7%, 55.9% and 47.7%, respectively, given a cumulative incidence of 29.2% of receiving a transplant at year 5. At implantation, 21.5% of patients were on extracorporeal life support. The overall rate of cardiogenic shock at implantation was 53%. The major complications were driveline infection (26.1%), pump pocket or cannula infection (12.6%), LVAD thrombosis (12.2%), ischaemic (12.8%) or haemorrhagic stroke (5.4%; all strokes 18.2%), non-cerebral haemorrhage (9.1%) and LVAD exchange (5.2%). The primary end point (survival) was stratified by age at surgery and by the type of device used, with inference from baseline profiles. The primary end point combined with an absence of complications (secondary end point) was also stratified by device type. CONCLUSIONS: The ASSIST-ICD registry provides a real-life picture of LVAD use in 20 of the 24 implant centres in France. Despite older average age and a higher proportion of patients chosen for destination therapy, survival rates improved compared to those in previous national registry results. This LVAD registry contrasts with other international registries because patients with implants have more severe disease, and the national policy for graft attribution is distinct. We recommend referring patients for LVAD earlier and suggest a discussion of the optimal timing of a transplant for bridged patients (more dismal results after the second year of support?).
引用
- Anselmi A, Galand V, Vincentelli A, et al. Current results of left ventricular assist device therapy in France: the ASSIST-ICD registry. Eur J Cardiothorac Surg. 2020. PMID: 32298439. doi:10.1093/ejcts/ezaa055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。